ATLANTA, GEORGIA—The new tyrosine kinase ibrutinib has shown “profound activity” in patients with chronic lymphocytic leukaemia—according to research presented at the American Society of H
ATLANTA, GEORGIA—The new tyrosine kinase ibrutinib has shown “profound activity” in patients with chronic lymphocytic leukaemia—according to research presented at the American Society of Hematology annual meeting. Dr Jan Burger from the MD Anderson Cancer Center in Houston, Texas, told Peter Goodwin about the results of using it in combination with rituximab.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/121209JanBurgerPODCASTLoRes.mp3]